Cargando…
Selumetinib Activity in Thyroid Cancer Cells: Modulation of Sodium Iodide Symporter and Associated miRNAs
Background: The MEK (mitogen-activated protein kinase)–inhibitor selumetinib led to increased radioiodine uptake and retention in a subgroup of patients suffering from radioiodine refractory differentiated thyroid cancer (RR-DTC). We aimed to analyse the effect of selumetinib on the expression of so...
Autores principales: | Wächter, Sabine, Wunderlich, Annette, Greene, Brandon H., Roth, Silvia, Elxnat, Moritz, Fellinger, Sebastian A., Verburg, Frederik A., Luster, Markus, Bartsch, Detlef K., Di Fazio, Pietro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6073679/ https://www.ncbi.nlm.nih.gov/pubmed/30018229 http://dx.doi.org/10.3390/ijms19072077 |
Ejemplares similares
-
Epigenetic Modifications in Thyroid Cancer Cells Restore NIS and Radio-Iodine Uptake and Promote Cell Death
por: Wächter, Sabine, et al.
Publicado: (2018) -
Dimerization of the Sodium/Iodide Symporter
por: Thompson, Rebecca J., et al.
Publicado: (2019) -
Individualised Multimodal Treatment Strategies for Anaplastic and Poorly Differentiated Thyroid Cancer
por: Wächter, Sabine, et al.
Publicado: (2018) -
Sodium iodide symporter-targeted gene therapy in glioblastoma
por: Nicola, Juan Pablo, et al.
Publicado: (2023) -
New! F-18-based PET/CT for sodium-iodine-symporter-targeted imaging!
por: Verburg, Frederik A., et al.
Publicado: (2020)